Shenzhen Lingfang Biopharmaceutical

Lingfang Pharmaceutical is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule therapies for autoimmune and inflammatory diseases. The company focuses on modulating key pathways in the innate and adaptive immune systems, with a particular emphasis on Toll-like receptor (TLR) antagonists and kinase inhibitors. Its lead program, LF001, is a potent TLR7/8 dual antagonist currently in clinical trials for systemic lupus erythematosus and other interferon-mediated conditions. Lingfang leverages a proprietary drug discovery platform to design highly selective compounds with optimized safety profiles for chronic administration.